Guest Contributor


Organizations:
Biofuture Fund, Business Development Bank of Canada, Exella Ventures, Future Fund Capital, GrowthWorks Capital, MDS Capital, NeuroMed Technologies Inc, Pictet & Cie, Royal Bank Capital Partners, and Trian Equities

NeuroMed raises $17 million to further clinical trials

Guest Contributor
February 12, 2001

NeuroMed Technologies Inc, Vancouver, has bucked the cooling trend in biotechnology financing raised $17 million to take its pain compounds up to the beginning of Phase II clinical trials. Its R&D into neur-onal calcium blockers aims to develop alternative painkillers to morphine and neuroprotective drugs for stroke. The second-round private financing was provided by GrowthWorks Capital, MDS Capital, Royal Bank Capital Partners, Trian Equities, Business Development Bank of Canada, Pictet & Cie, Biofuture Fund, Exella Ventures, Future Fund Capital and several individuals....


Other News

V-RQ funds multidisciplinary research projects

iCORE helps fund wireless research appointments

Alberta Synchrotron Institute gets $5.1 million in funding

MDS Proteomics and IBM strike major collaboration






Events For Leaders in
Science, Tech, Innovation, and Policy


Discuss and learn from those in the know at our virtual and in-person events.



See Upcoming Events










You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in






Top

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.